Zevra Therapeutics Reports Q4 Earnings

Specialty pharmaceutical company exceeds revenue expectations

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Zevra Therapeutics, Inc., a specialty pharmaceutical company based in Celebration, Florida, reported net income of $12.2 million in its fourth quarter. The company posted revenue of $34.1 million in the period, exceeding analyst forecasts.

Why it matters

Zevra Therapeutics' strong financial performance in Q4 and for the full year 2026 demonstrates the company's ability to grow its revenue and profitability, which is important for its long-term success and ability to invest in research and development of new pharmaceutical products.

The details

On a per-share basis, Zevra Therapeutics reported net income of 19 cents. Earnings, adjusted for asset impairment costs, came to $1.16 per share. For the full year 2026, the company reported profit of $83.2 million, or $1.35 per share, on revenue of $106.5 million.

  • Zevra Therapeutics reported its Q4 2026 earnings on March 9, 2026.

The players

Zevra Therapeutics, Inc.

A specialty pharmaceutical company based in Celebration, Florida.

Got photos? Submit your photos here. ›

The takeaway

Zevra Therapeutics' strong financial performance in Q4 and for the full year 2026 demonstrates the company's ability to grow its revenue and profitability, positioning it for continued success in the specialty pharmaceutical market.